GOMEKLI (mirdametinib)

Resources to guide you

Actor portrayal.

Supporting your journey with GOMEKLI

Considering GOMEKLI?

The downloadable resources below can help you learn more about GOMEKLI and make the most out of conversations with your healthcare provider.

Image of the GOMEKLI™ (mirdametinib) Patient Brochure PDF

Is GOMEKLI right for me?

Questions to consider when talking to your healthcare provider about treatment.

Image of the GOMEKLI™ (mirdametinib) Patient Brochure PDF for adults and children. Please see important safety information and Patient Information.

GOMEKLI patient brochure (adults and children)

Get information on GOMEKLI, including its potential benefits, possible side effects, dosing, and more.

GOMEKLI Patient Brochure PDF for adults

GOMEKLI patient brochure (adults)

See how adults may experience GOMEKLI, the first and only approved treatment for people 18+ with NF1-PN.

Getting started on GOMEKLI?

The following resources were designed to prepare you for your journey with GOMEKLI.

Image of the Getting Started Guide PDF

Getting started guide

Find helpful information on what to expect from GOMEKLI and the support offered through SpringWorks CareConnections.

Image of the SpringWorks CareConnections™ brochure PDF

SpringWorks CareConnections™ brochure

A detailed look at free, personalized support from SpringWorks CareConnections.

Image of the Personalized Treatment Journal PDF

Personalized treatment journal

Keep notes on how you’re feeling while taking GOMEKLI to let your care team know how you’re doing.

The GOMEKLI Digital Companion​

The GOMEKLI Digital Companion

This free resource can help you stay on track with your treatment, provide educational support, and more.
Image onscreen:
GOMEKLI (mirdametinib) and Medisafe logos

Text onscreen:
Welcome to the GOMEKLI Digital Companion

Text onscreen:
You have recently been prescribed GOMEKLI (mirdametinib)

Text onscreen:
It’s completely normal to have questions as you start your treatment journey

Text onscreen:
Can I create reminders and get notifications to help me stay on track?

How can I learn more about GOMEKLI (mirdametinib)?

Where can I find more information about my condition?

Are there financial assistance options available, and am I eligible for support?

How can I remember all my upcoming doctor appointments?

How can I prepare for my appointments?

Image onscreen:
The GOMEKLI Digital Companion screens on an iPhone

Text onscreen:
To support you or your loved one’s treatment with GOMEKLI (mirdametinib), SpringWorks Therapeutics has developed the GOMEKLI Digital Companion available on Medisafe, a top-rated medication management app

Text onscreen:
The GOMEKLI Digital Companion:
Supports patients on GOMEKLI (mirdametinib) with medication and refill reminders

Provides access to educational content

Helps facilitate engagement with your Nurse Advocate and the SpringWorks CareConnections™

Text onscreen:
For a personalized experience, enroll in SpringWorks CareConnections™ and receive an invite to the GOMEKLI Digital Companion on Medisafe

Image onscreen:
Text message invite to GOMEKLI Digital Companion on iPhone from SpringWorks CareConnections™

Text onscreen:
Download the Medisafe app

Image onscreen:
Google Play and App store badges. Image of Medisafe app in App Store on an iPhone

Text onscreen:
Enter the code you received from your Nurse Advocate

Text onscreen:
Continue to enroll into the GOMEKLI Digital Companion on Medisafe

Text onscreen:
Complete your profile

Text onscreen:
Create your account

Text onscreen:
Next, add your medication reminders

Don’t forget, you can also track all your medications, vitamins, and supplements with Medisafe.*

*Be sure to inform your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements

Text onscreen:
You are enrolled in the GOMEKLI Digital Companion!

Text onscreen:
The GOMEKLI Digital Companion features a dynamic content feed offering personalized support WHEREVER YOU GO. This can be found in the ‘For You’ tab

Text onscreen:
And can provide updates on your coverage status

Text onscreen:
You can also set reminders to take GOMEKLI (mirdametinib) and receive ongoing encouragement

Text onscreen:
The GOMEKLI Digital Companion features a library of supportive and educational content in the ‘Explore’ tab

Text onscreen:
And educational content about your GOMEKLI (mirdametinib) treatment

Text onscreen:
At the tap of a button, you can request a call from your Nurse Advocate

Text onscreen:
Not enrolled in SpringWorks CareConnections™? Enrolling is simple. Call at 844-CARES-55 (844-227-3755) Monday – Friday, 8AM – 10PM ET

Image onscreen:
SpringWorks CareConnections™ logo

Text onscreen:
Please note that you can access the GOMEKLI Digital Companion without enrolling in SpringWorks CareConnections™. However, for a personalized experience and to unlock additional features, we recommend enrolling in SpringWorks CareConnections™.

Image onscreen:
GOMEKLI (mirdametinib) and Medisafe logos

Text onscreen:
Remember your healthcare provider is your primary source of information. Talk to your healthcare provider if you have any questions about your treatment.

Text onscreen:
If you encounter any issues while enrolling in the GOMEKLI Digital Companion and need technical support, please email programsupport@medisafe.com to connect with a member of the Medisafe Customer Support Team.

©2025 SpringWorks Therapeutics, Inc. All rights reserved. GOMEKLI and SpringWorks CareConnections are trademarks of SpringWorks Therapeutics, Inc. C_GOM_US_0283
This free resource can help you stay on track with your treatment, provide educational support, and more.

Download the Medisafe app to access the GOMEKLI Digital Companion

Find a doctor

Finding a healthcare provider who is familiar with NF1 is the most important thing you can do for yourself or your loved one. Use this tool to locate an experienced healthcare provider near you.

Healthcare providers in this database may be recognized by the NF Network, or be members of the Children’s Tumor Foundation’s NF Clinic Network, as noted in their profiles.

These websites also feature tools that can help you locate healthcare providers throughout the US who are familiar with NF1.

SpringWorks Therapeutics is providing these independent resources to help patients find an NF1 treater by region, but SpringWorks Therapeutics had no role in their development. Their inclusion on this website does not represent an endorsement or a recommendation from SpringWorks Therapeutics for any center or physician.

NF organizations*

If you’re living with or caring for someone with NF1-PN, there are a number of advocacy groups where you can get information or connect with others in the NF community.

The NF Collective is a group of organizations dedicated to improving the lives of NF patients and their families by providing accurate and reliable information about NF resources and caregivers. The Children’s Tumor Foundation and Littlest Tumor Foundation are part of the NF Collective.

Independent Patient Assistance Foundations

Financial assistance may be available through independent foundations that are not controlled by or otherwise affiliated with SpringWorks Therapeutics. These foundations may be able to assist with copays, premiums, patient education, social services, etc.

SpringWorks Therapeutics does not influence or control the operations of independent patient assistance foundations and cannot guarantee assistance will be provided. Details and eligibility requirements can be found directly on the individual foundation websites.

Explore additional foundations that may be able to help with financial assistance

*SpringWorks Therapeutics is providing these websites and resources to help patients find more information about NF1-PN, but their inclusion does not represent an endorsement or a recommendation from SpringWorks Therapeutics for any group or organization. Any organization listed is independent of SpringWorks Therapeutics.

What is GOMEKLI?

GOMEKLI (mirdametinib) is a prescription medicine used to treat adults and children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cause symptoms and cannot be completely removed by surgery.

It is not known if GOMEKLI is safe and effective in children under 2 years of age.

Important Safety Information

Before taking GOMEKLI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have eye problems
  • Have heart problems
  • Are pregnant or plan to become pregnant. GOMEKLI can harm your unborn baby

    Females who are able to become pregnant:

    • Your healthcare provider should check to see if you are pregnant before you begin treatment with GOMEKLI.
    • Use effective birth control (contraception) during treatment with GOMEKLI and for 6 weeks after your last dose.
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with GOMEKLI.

    Males with female partners who are able to become pregnant:

    • Use effective birth control (contraception) during treatment with GOMEKLI and for 3 months after your last dose.
    • Tell your healthcare provider right away if your female partner becomes pregnant or thinks she may be pregnant during treatment with GOMEKLI.
  • Are breastfeeding or plan to breastfeed. It is not known if GOMEKLI passes into your breastmilk.
    • Do not breastfeed during treatment with GOMEKLI and for 1 week after your last dose.
    • Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I take GOMEKLI?

  • Take GOMEKLI exactly as your healthcare provider tells you to take it. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with GOMEKLI if you develop certain side effects.
  • Take GOMEKLI twice a day, about 12 hours apart, for 21 days, followed by 7 days off treatment, to complete a 28-day treatment cycle. Your healthcare provider will decide how many treatment cycles are right for you.
  • Take GOMEKLI with or without food.
  • GOMEKLI comes in two different dosage forms, GOMEKLI capsules and GOMEKLI tablets for oral suspension. Your healthcare provider will decide the dosage form and dose of GOMEKLI that is right for you.
  • If you take GOMEKLI capsules: Swallow each capsule whole with drinking water. If more than 1 capsule is required, swallow 1 capsule at a time. Do not open, break or chew the capsules.
  • If you take GOMEKLI tablets for oral suspension, either:
    • Swallow each tablet for oral suspension whole with drinking water. If more than 1 tablet is required, swallow 1 tablet at a time.
    • OR

    • Disperse the tablets for oral suspension in drinking water to make a liquid (suspension) before you take or give GOMEKLI.

    See the “Instructions for Use” that come with your medicine for instructions on how to prepare and take GOMEKLI tablets for oral suspension.

  • If you miss a dose of GOMEKLI, skip the missed dose and take your next dose at your regularly scheduled time.
  • If you vomit at any time after taking GOMEKLI, do not take an additional dose. Take your next dose at your regularly scheduled time.

What are the possible side effects of GOMEKLI?

GOMEKLI may cause serious side effects, including:
  • Eye problems. GOMEKLI may cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment with GOMEKLI. Tell your healthcare provider right away if you get any of the following signs or symptoms of eye problems:
    • Blurred vision
    • Loss of vision
    • Other changes to your vision
  • Heart problems. GOMEKLI may lower the amount of blood pumped by your heart, which is common in children during treatment with GOMEKLI and can also be severe. Your healthcare provider will do tests before you start GOMEKLI treatment, every 3 months during your first year of treatment, and then as needed to make sure your heart is working properly. Tell your healthcare provider right away if you get any of the following signs or symptoms of heart problems:
    • Coughing or wheezing
    • Shortness of breath
    • Swelling of your ankles and feet
    • Tiredness
    • Increased heart rate
  • Skin problems. Skin rashes are common with GOMEKLI in both adults and children and can also be severe. GOMEKLI can also cause hair loss (alopecia). Tell your healthcare provider if you develop any of the following signs or symptoms of skin problems:
    • Flat skin rash
    • Raised bumps on the skin
    • Skin bumps that look like acne
    • Skin redness
    • Itchy rash
    • Peeling skin

The most common side effects of GOMEKLI in adults include:

  • Diarrhea
  • Nausea
  • Muscle, joint, and bone pain
  • Vomiting
  • Tiredness
The most common severe abnormal blood tests in adults include an increased enzyme called creatine phosphokinase (CPK).

The most common side effects of GOMEKLI in children include:

  • Diarrhea
  • Muscle, joint, and bone pain
  • Stomach (abdominal) pain
  • Vomiting
  • Headache
  • Skin redness, swelling, or pain around the fingernails or toenails
  • Nausea
The most common severe abnormal blood tests in children include decreased white blood cell (neutrophil) counts and increased CPK.
GOMEKLI may cause fertility problems in females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all of the possible side effects of GOMEKLI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is GOMEKLI?

GOMEKLI (mirdametinib) is a prescription medicine used to treat adults and children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cause symptoms and cannot be completely removed by surgery.

It is not known if GOMEKLI is safe and effective in children under 2 years of age.

Please click here for full Prescribing Information, including Patient Information and Instructions for Use.
Please click here for full Prescribing Information, including Patient Information and Instructions for Use.